Genetic Technologies : Quarterly Activities Report & Appendix 4C

Genetic Technologies Q2 FY22 Cash Flow Results Q2 momentum sets the stage for a strong FY22

onlyMelbourne, Australia, 19 January 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, 'Company', 'GTG', 'geneType'), a diversified Genomics and AI driven preventative health business provides its results for the quarter ended 31 December 2021.

Highlights:
use				Customer Reciepts (A$'000)
• Solid cash balance of A$13.5 million and increased customer
	receipts of A$1.8 million further extending runway for growth			$1,809
• 'One company two brands' approach leverages EasyDNA
	acquisition with launch of the Multi-Test product
• Multi-Test technical validation complete and submitted to
personal	NATA1 and CMS2 for final regulatory approval ahead of the
commercial release
• Multi-Test to address a burgeoning market determining		$850
	personal risk of developing a range of serious diseases including:
		o	breast cancer
		o	colorectal cancer
		o	ovarian cancer
		o	prostate cancer	$68
		o	coronary artery disease
		o	type 2 diabetes	4QFY21	1QFY22	2QFY22
• US patent application for novel geneType COVID-19 Risk Test has been accepted and cross validation
	study completed in independent cohort confirming test performance and utility
• Study of 200,000 participants presented at 2021 San Antonio Breast Cancer Symposium validating the
For	risk model with an expanded panel of 313 Single Nucleotide Polymorphisms (SNPs)
1	National Association of Testing Authorities, Australia
	2 Centers for Medicare & Medicaid Services

Genetic Technologies Limited	60-66 Hanover Street
www.gtglabs.com	Fitzroy Victoria 3065
[e-mail]	Australia
ABN 17 009 212 328	[phone]

• EasyDNA distribution network provides access to a significant addressable market with, 70 websites in

only	40 countries and further engagement with IBX on the COVID-19 Risk Test
•	COVID-19 Risk Test - expanded US patient access with new partnership agreement signed with 1Health
	and IBX. Cross validation study completed, independent cohort confirms test performance and utility.
	Emergence of new strains of Covid 19, such as Omicron, highlight the importance and utility of GTG's
	COVID-19 Risk Test.

EasyDNA Acquisition and geneType Brand Launch

Genetic Technologies announced the acquisition of EasyDNA in July 2021 and completed the settlement useprocess in August 2021. The four months since settlement focused on the integration of our people,

products and EasyDNA platform to deliver a "One Company-Two Brand" approach for GTG. This will drive a clearer marketing and engagement structure for new and existing products coming to market. Importantly, further integration will continue over the coming quarters as the Company works to further leverage and grow the existing network of 70 websites across 40 countries.

Overall, the Company is in a strong position with a portfolio of high-quality products both in the market and personalunder development and a substantial international platform for the distribution of the Direct-to-Consumer

product base via EasyDNA.

As part of the EasyDNA integration, the Company announced the launch of the geneType rebrand in November 2021. The geneType brand is the overarching business and brand, while the EasyDNA brand with its existing network, will represent the consumer facing brands and products and drive increased awareness

f GTG's product portfolio.

Total cash receipts for the quarter from EasyDNA were A$1.8 million in line with acquisition expectations. The Company is focused on further embedding the acquisition with the inclusion of the Multi-Test and

xpects to see continued solid growth in revenue across all brands and products.

Commercialisation and Product Overview

The Company's strategy to commence commercialisation and enhance the product distribution network is well underway. Key avenues for commercialisation of launched products currently include the consumer-

Forinitiated testing and online sales and marketing platform (CIT) available in Australia and the US. With the

recent inclusion of the EasyDNA business the Company intends to leverage this platform to enhance the visibility and awareness of its existing products.

Core products for release include GTG's geneType for Breast Cancer, geneType for Colorectal Cancer and the COVID-19 Risk Test with the commercial release of the Company's Multi-Test to cover both Colorectal

Genetic Technologies Limited	60-66 Hanover Street
www.gtglabs.com	Fitzroy Victoria 3065
[e-mail]	Australia
ABN 17 009 212 328	[phone]

Cancer and Breast Cancer in addition to Prostate Cancer, Ovarian Cancer, Coronary Artery Disease and Type 2 Diabetes.

onlyGTG now have distribution coverage in Australia and the US and have identified Europe and the UK as further expansion opportunities for the Company. The Company is assessing the European CE certification requirements for its products and will update the market on its progress within these regions as further clarity on timing is obtained. An Asian market entry for relevant products will also be assessed in due course.

Multi-Test Product Commercial Release

useIn late December 2021, the Company confirmed it is set to release phase one of the Multi-Test, subject to receiving final regulatory approval and confirms that all regulatory submissions to NATA and CMS have been completed. NATA completed their onsite audit of GTG's Melbourne laboratory on December 15, 2021. The certifying body is preparing their final documentation on the audit in the coming weeks.

The phase one launch is the culmination of 10+ years of research and development and include Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Coronary Artery Disease and Type 2 diabetes. The Company is now focused on finalising commercial distribution opportunities via our EasyDNA brand

personalnd through our existing partner network with IBX, 1 Health and Vitagene.

The direct-to-consumer genetic testing market represents a significant growth opportunity for GTG, the total worldwide market is expected to grow from US$1.2 billion in 2020 to US$2.6 billion3 in 2025, an

i crease of US$1.4 billion. The growth of the DTC segment is driven by a number of factors including a broader understanding of the growing demand for disease risk analysis.

Of particular relevance to GTG's Multi-Test development is the emergence of Precision Medicine and its ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease. GTG's Risk Assessment Tests are an important part of eliminating the traditional "one size fits all" approach, enabling preventive or therapeutic measures to be concentrated on patients who will gain the most benefit, significantly improving patient outcomes and health economics.

COVID-19 Risk Test

In December 2021, the Company announced a new partnership to expand access to the COVID-19 Risk Test Forin the US through its agreement with IBX and 1health on their 'Vitagene' platform directly from

https://genetype.com/for-individuals/COVID-19/.

1health is a leading US-based cloud platform service provider for diagnostic test management. 1health has built infrastructure that helps laboratories, such as IBX and their customers, connect patients to testing and

3 https://www.technavio.com/report/direct-to-consumer-genetic-testing-market-size-industry-analysis&nowebp

Genetic Technologies Limited	60-66 Hanover Street
www.gtglabs.com	Fitzroy Victoria 3065
[e-mail]	Australia
ABN 17 009 212 328	[phone]

care. 1health's services will be managed in partnership with IBX under our three-yearco-exclusive licence agreement previously announced on March 3, 2021.

onlyThe Company has continued to expand and develop the geneType COVID-19 Risk Test, having recently

completed a cross-validation study on a European data set confirming the test performance metrics. A paper describing the study has now been submitted to a peer-reviewed journal and will be released upon

publication. The emergence of the Omicron variant underscores the importance of being able to identify those patients, whether vaccinated or not, who are at greater risk of developing severe disease.

The geneType COVID-19 Risk Test is designed to predict disease severity in people aged 18 and older, using genetic and clinical information providing a risk score that can be used to understand a person's risk of

usecontracting a serious case of COVID-19. In addition, employers, governments, and other public health entities may use the data to make informed decisions about disease risk, treatment options, and importantly guiding vaccination and booster priorities. According to the Centers for Disease Control and Prevention, as at 15 January 2022, only 74.9% of the US population had received at least one shot of a COVID-19 vaccine, leaving approximately 83 million Americans unvaccinated. The geneType COVID-19 Risk

Test could assist these people to better understand their risk of severe disease, while providing those who are vaccinated (approximately 249 million people) with an incentive to obtain a booster if they are at high

personalrisk of severe disease.

Research and Publications

Over the quarter, the Company has continued to invest in its product development supporting a self-funded

study in collaboration with the Institute of Public Health in St Louis, and continued progress with the Multi- Test slated for release in the coming months.

In December 2021, GTG's Director of Clinical Affairs, Dr Erika Spaeth presented a poster at the San Antonio Breast Cancer Symposium. In her presentation Dr Spaeth released new data that demonstrated a next

generation version of the Company's geneType Breast Cancer Test with an expanded panel of 313 SNPs showed improved discrimination and calibration over traditional clinical models. The study included over 200,000 women and highlighted GTG's commitment to the ongoing development of geneType Breast Cancer Risk Test.

The Company is pleased to report a further peer-reviewed research publication entitled "Ability of known colorectal cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study within the UK Biobank"

ForGafni A, Dite GS, Spaeth Tuff E, Allman R, Hopper JL (2021) was published on PLOS

The study describes how the addition of a polygenic risk score to a family history model improves the stratification and discriminatory performance of both 10 year and full lifetime risk using a prospective population-based cohort within the UK Biobank.

Genetic Technologies Limited	60-66 Hanover Street
www.gtglabs.com	Fitzroy Victoria 3065
[e-mail]	Australia
ABN 17 009 212 328	[phone]

Current screening guidelines in the UK, USA and Australia focus solely on family history and age for risk prediction, even though the vast majority of the population do not have any family history. The results

onlysupport the view that a combined polygenic risk score and first-degree family history model could be used to improve risk stratified population screening programs.

Corporate and Financial Overview

At the end of the quarter GTG has A$13.5 million in cash and cash equivalents, providing adequate runway to support the commercialisation initiatives for the Multi-Test and COVID-19 Risk Test.

Net cash used in investing activities of A$3.5 million in the two quarters to December 2021 quarter

usecomprised mainly the acquisition of and investment in the EasyDNA business and assets.

Cash outflows used in operating activities were A$2.2 million. Cash receipts from customers for the

December quarter were A$1.8 million (primarily associated with EasyDNA product sales and the building sales of GeneType for Breast Cancer and Colorectal Cancer products), grants and interest received was

A$72k. Expenses incurred on a cash basis during the quarter included research and development and staff costs of A$1.3 million associated with the geneType product development. Additionally, the Company incurred A$671k associated with targeted advertising and marketing with expenditure expected to increase

personals the company enhances its sales and marketing focus in future quarters. For

During the December 2021 quarter, net cash payments to directors were A$68k comprising A$51k as director fees and A$17k as consulting fees.

Outlook

The Company remains focused on the commercialisation opportunities for the Multi-Test, continued leveraging the EasyDNA brand and product suite to grow the revenue base, further investment in R&D to enhance our Multi-Test offering and COVID-19 Risk Test and continuing to remain at the cutting edge of genetic testing and preventative health.

Commenting on the forward outlook, Simon Morriss stated: "We are pleased with the progress made over this quarter and with the integration of the EasyDNA team while continuing to advance our product commercialisation pathway opportunities.

Genetic Technologies Limited	60-66 Hanover Street
www.gtglabs.com	Fitzroy Victoria 3065
[e-mail]	Australia
ABN 17 009 212 328	[phone]